SEOUL, May 30- South Korea's Samsung Bioepis said on Monday its biosimilar of Johnson& Johnson's blockbuster rheumatoid arthritis drug Remicade has received final approval from European regulators, paving the way for its second product launch in Europe. Samsung Bioepis, an unlisted arm of South Korea's top conglomerate Samsung Group, also submitted the... » Read More
Billionaire activist investor (It seems it's become almost de rigueur to put those three words before his name) Carl Icahn is apparently so busy waging a proxy fight against biotechs Amylin Pharmaceuticals and Biogen Idec that he hasn't posted a new blog entry in nearly a month.
As walk-in clinics at stores like CVS and Wal-Mart offer convenient alternatives to doctors’ offices and hospital emergency rooms, some hospitals are fighting back - with walk-in clinics at some of those same retailers.
Imagine my surprise when I got an email over the weekend from "Diabetic Investor" newsletter editor David Kliff informing me that Amylin Pharmaceuticals is quoting me in a letter to shareholders.
The Glaxo announcement contained the results of the first head-to-head study of GSK’s Cervarix versus Merck’s Gardasil. They’re the shots for the sexually transmitted virus that can cause genital warts and cervical cancer. MRK’s is already on the market. GSK’s has been delayed in getting there.
A new study shows that Merck's Gardasil vaccine protects some young women from a strain of a sexually transmitted disease that can lead to cervical cancer for nearly a decade.
Out of nowhere late yesterday the FDA approved VNDA's schizophrenia drug with the funky name Fanapt.
The Obama administration plans to spend $1.1 billion over the next few years on comparative studies to determine the effectiveness of competing treatments for common conditions like back pain, heart disease and prostate cancer.
Against the backdrop of President Obama's healthcare reform effort, the main lobbying group for the generic drug industry says the U.S. healthcare system saved nearly three-quarters of a trillion dollars over the past ten years on generic drugs.
It's a new world. Before Roche bought Genentech, stock-moving drug development milestones for DNA were closely followed by the news media, analysts and investors. But because the Swiss drugmaker Roche only trades over-the-counter in the U.S., the information isn't as "actionable" as it used to be when DNA was around.
You gotta love a good proxy fight, especially when you have one of the kings of shareholder activism, Carl Icahn, in the ring. And lately, I've been getting bombarded by emails from representatives of all corners.
Fiesta time started a little earlier than expected for investors in Eli Lilly, Amylin Pharmaceuticals and Alkermes. The companies had said they would file for Food and Drug Administration approval of the once-a-week version of the diabetes drug Byetta in the second quarter, but most analysts thought that meant June.
Whenever a politician, government agency or company puts out news late on a Friday chances are it probably isn't good or it's stuff they'd like to just slip under the door.
Well, it didn't take long. A little more than a month after Roche swallowed Genentech, Dr. Susan Desmond-Hellmann may be headed out the door sooner than anyone thought.
have two reasons to exhale on this TGIF. My month-long stint on the graveyard shift anchoring "Worldwide Exchange" is over and Dendreon is done...for now. After all, Dendreon and its prostate cancer treatment Provenge is the story that just keeps on giving.
Shares of San Diego-based Sequenom are sinking on huge trading volume. The company shocked investors after the closing bell yesterday when it issued this press release announcing that its data couldn't be trusted.
The herky-jerky, stop-and-go cab ride I'm taking right now to O'Hare ain't nuthin' compared to yesterday's roller coaster ride at Chicago's McCormick Place. And can I just say? Is Dendreon a giant magnet for high drama and intrigue or what?
Here we go again. When I was relatively new on this beat I was thrown into covering the bird flu scare. At the time, many experts said it wasn't a question of if, but when it would come to the U.S. I'm still waiting. And I hope we're all waiting forever.
I didn't have much of a weekend. I was putting out swine flu fires via work emails and dealing with a really bad allergy attack. Plus, it kinda gets cut short by having to go to bed so early (6 o'clock) in order to anchor "Worldwide Exchange" at 4 a.m. ET.
Next week's gonna be crazy, especially Tuesday aka "Dendreon Day." Shortly after I'm done anchoring "Worldwide Exchange" early Monday morning I'll be flying to Chicago to cover the highly anticipated data release on DNDN's Provenge. That's the name of the biotech company's unique, experimental treatment for prostate cancer.
At Pfizer's annual shareholder meeting in Atlanta this morning, investors approved a version of "Say on Pay."